Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply
N Engl J Med
.
2022 Dec 29;387(26):2482-2485.
doi: 10.1056/NEJMc2208182.
Authors
Finnian R Mc Causland
1
,
Ajay K Singh
1
,
Brian L Claggett
1
,
Kevin Carroll
2
,
Janet Wittes
3
,
John J V McMurray
4
,
Vlado Perkovic
5
,
Steven Snapinn
6
,
Renato D Lopes
7
,
Scott D Solomon
8
Affiliations
1
Brigham and Women's Hospital, Boston, MA ajay_singh@hms.harvard.edu.
2
KJC Statistics, Macclesfield, United Kingdom.
3
Wittes, Washington, DC.
4
University of Glasgow, Glasgow, United Kingdom.
5
University of New South Wales, Sydney, NSW, Australia.
6
Seattle-Quilcene Biostatistics, Seattle, WA.
7
Duke Clinical Research Institute, Durham, NC.
8
Brigham and Women's Hospital, Boston, MA.
PMID:
36577112
DOI:
10.1056/NEJMc2208182
No abstract available
Publication types
Letter
Comment
MeSH terms
Anemia* / chemically induced
Barbiturates / adverse effects
Cardiovascular Diseases* / chemically induced
Cardiovascular Diseases* / prevention & control
Humans
Renal Dialysis
Renal Insufficiency, Chronic* / therapy
Substances
GSK1278863
Barbiturates